• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas launches wearable insulin delivery device in Italy

October 19, 2018 By Sarah Faulkner

Valeritas V-Go device - updatedValeritas (NSDQ:VLRX) said today that its wearable insulin delivery device has launched in Italy.

The Bridgewater, N.J.-based company inked an exclusive distribution deal with Movi SpA to bring its V-Go device to the more than 2 million people in Italy with Type 2 diabetes.

“We are happy to announce the V-Go Wearable Insulin Delivery device is now available in Italy for patients with Type 2 diabetes,” Valeritas CEO John Timberlake said in prepared remarks. “We are excited that the 2 million people in Italy diagnosed with Type 2 diabetes now have the option of a simple, affordable, all-in-one insulin delivery system.”

“We are proud to be the first European country to officially introduce this new simple and effective device that will help people with Type 2 diabetes better control their glucose and improve their quality of life,” Movi president Enrico Piero Bassani added.

According to the terms of the distribution deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing while Movi will handle sales, marketing, customer support and distribution activities.

Also this year, Valeritas launched its V-Go device in Australia and New Zealand.

The company said earlier this week that it plans to offer 37,593,984 shares of its common stock in an effort to raise $50 million in gross proceeds.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Reader Interactions

Comments

  1. Jos Groeskamp says

    October 24, 2018 at 12:20 am

    Please send me information re this device. This is for a friend that had to switch to the Medtronic device and does not like this at all. Looking for alternative options now.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS